Unmasking the Masquerader: A Clinician's Guide to Recognising and Working Up Autoinflammatory Syndromes

Dr Neeraj Manikath , claude.ai

Corresponding Author: Department of Internal Medicine | Postgraduate Medical Education

Conflicts of interest: None declared | Funding: None

Abstract

Autoinflammatory syndromes (AIS) represent a rapidly evolving frontier in internal medicine — a group of disorders defined by dysregulated innate immunity, episodic or chronic systemic inflammation, and a diagnostic odyssey that can span years. Unlike autoimmune diseases driven by adaptive immunity and autoantibodies, AIS arise from intrinsic defects in inflammasome signalling, cytokine regulation, or pattern recognition pathways. Clinicians who do not think of AIS will not diagnose AIS — and their patients pay the price in organ damage, unnecessary immunosuppression, and diminished quality of life. This review equips the postgraduate trainee and practising consultant with a structured, bedside-first approach to recognising, investigating, and managing these conditions, incorporating the latest advances in genomics, targeted biologics, and treat-to-target strategies.

1. Opening Vignette: The Fever No One Could Explain

A 28-year-old nurse is referred to your general medicine clinic. Over the past four years she has had eleven hospital admissions — each time with fever to 39.5°C, severe sore throat, cervical lymphadenopathy, and a serum ferritin that peaks above 8,000 µg/L before normalising within a week. Rheumatology found no autoantibodies. Haematology excluded lymphoma twice. Infectious disease deemed her "culture-negative." She has received six empirical antibiotic courses, two short steroid bursts, and one inadvisable trial of colchicine for "presumed FMF." She is now anxious, medically traumatised, and beginning to believe nothing is truly wrong with her.

You are the twelfth clinician she has seen.

The diagnosis — Adult-onset Still's Disease — was hiding in plain sight. The quotidian fever pattern, salmon-coloured evanescent rash present only during febrile episodes, arthralgia, sore throat, and hyperferritinaemia are textbook. What failed her was not medicine's knowledge base, but medicine's pattern recognition.

This is the story of autoinflammatory syndromes: conditions where the inflammation is real, the suffering is profound, and the diagnosis requires you to think differently.

2. Framing the Problem: Why AIS Is No Longer a Rarity

The global prevalence of monogenic autoinflammatory diseases is estimated at 1–5 per 10,000, but this almost certainly underestimates the true burden due to misclassification and underdiagnosis. Familial Mediterranean Fever (FMF) alone affects over 150,000 individuals worldwide, with highest prevalence in Mediterranean, Middle Eastern, and South Asian populations. Adult-onset Still's Disease has an incidence of approximately 0.16–0.4 per 100,000 per year globally. With the democratisation of next-generation sequencing and wider awareness of inflammasome biology, new conditions continue to be described — over 45 monogenic AIS have been formally catalogued since 2009.

The core insight: Any patient with recurrent unexplained fever, elevated inflammatory markers that normalise between episodes, and organ involvement that does not fit a straightforward infectious or autoimmune diagnosis should prompt consideration of AIS.

3. Pathophysiology — Only What You Need at the Bedside

Understanding AIS does not require a PhD in molecular biology. The clinically actionable framework rests on three pillars:

3.1 The Innate Immune System as the Culprit

Unlike rheumatoid arthritis or SLE — where T-cells and B-cells misbehave — AIS arise from aberrant innate immune signalling. The key players are:

Inflammasomes — intracellular multiprotein complexes (particularly NLRP3) that sense danger signals and activate caspase-1, leading to IL-1β and IL-18 processing and release
Pattern recognition receptors (Toll-like receptors, NOD proteins) that misfire in the absence of genuine pathogen challenge
Type I interferon signalling pathways — overactivated in interferonopathies such as STING-associated vasculopathy with onset in infancy (SAVI) and Aicardi-Goutières syndrome

3.2 The Cytokine Logic of AIS

Cytokine	Key AIS	Therapeutic Implication
IL-1β	FMF, CAPS, DIRA, TRAPS	IL-1 blockers (anakinra, canakinumab) are highly effective
IL-6	AOSD, Castleman disease	Tocilizumab, siltuximab
IL-18	Macrophage Activation Syndrome, AOSD	Emerging: tadekinig alfa
TNF-α	TRAPS (partial), Behçet's	Etanercept less effective; infliximab preferred
Type I IFN	Interferonopathies	JAK inhibitors (baricitinib, ruxolitinib)

Why this matters: The cytokine profile of a disease predicts its therapeutic target. Getting the pathophysiology right is not academic — it directly determines which biologic you reach for.

3.3 Gain-of-Function vs Loss-of-Function Genetics

Most monogenic AIS follow a gain-of-function pattern — a mutation that constitutively activates inflammatory pathways even without external triggers. FMF is the notable exception, being autosomal recessive with loss-of-function mutations in MEFV encoding pyrin. Understanding this matters when counselling families about inheritance risk.

4. 🪙 Clinical Pearls — High-Yield Bedside Observations

Pearl 1 — The Fever Pattern Is Diagnostic, Not Decorative

Most clinicians record "fever present" and move on. In AIS, the character, periodicity, and synchrony of fever with other symptoms carry diagnostic weight:

Quotidian fever (once-daily spike, typically afternoon, returning to normal each morning): AOSD
Periodic fever every 4–6 weeks: PFAPA (Periodic Fever, Aphthous stomatitis, Pharyngitis, Adenitis)
Every 3–4 weeks in childhood: Cyclic neutropaenia — check serial neutrophil counts
Irregular but episodic, lasting 3–7 days: FMF, TRAPS
Continuous with flares: CAPS (particularly MWS and NOMID variants)

🪙 Pearl: Ask the patient to keep a fever diary with dates, duration, and associated symptoms for at least 3 months before concluding the pattern is non-periodic. Many diagnoses become obvious on paper.

Pearl 2 — Inflammatory Markers Tell a Story If You Read the Trend

In AIS, inflammatory markers (CRP, ESR, ferritin, SAA — serum amyloid A) are typically markedly elevated during attacks and normalise completely between attacks. This episodic normalisation is a cardinal feature that distinguishes AIS from chronic inflammatory diseases such as RA or IBD, where markers remain persistently elevated.

🪙 Pearl: Check CRP and ESR both during an attack AND between attacks. Inter-attack normalisation strongly supports AIS. Persistent elevation should prompt rethinking the diagnosis.

Pearl 3 — The Rash Chronology

FMF: erysipelas-like erythema over the dorsum of the foot and ankle — classically unilateral, warm, and tender, mimicking cellulitis (but responds to colchicine, not antibiotics)
AOSD: salmon-coloured, evanescent, non-pruritic macular rash synchronous with fever spikes — it appears during fever and disappears as the fever breaks; many physicians miss it because they don't examine during the fever
CAPS/MWS: urticarial rash — but critically, it is not pruritic (unlike true urticaria), does not respond to antihistamines, and worsens with cold exposure (especially in FCAS — familial cold autoinflammatory syndrome)

5. 🦪 Oysters — Hidden Gems Most Clinicians Miss

Oyster 1 — Amyloidosis: The Silent Clock Ticking

Untreated FMF and TRAPS carry a substantial risk of AA amyloidosis — deposition of serum amyloid A protein in kidneys, liver, spleen, and gut. The kidneys are the primary target. Proteinuria in a patient with recurrent fever is amyloidosis until proven otherwise. Spot urine protein:creatinine ratio should be checked annually in all patients with FMF and TRAPS. A renal biopsy with Congo red staining showing apple-green birefringence under polarised light is diagnostic. Colchicine prevents amyloidosis in FMF — this is, in fact, the most important mortality-reducing effect of colchicine treatment, not just symptom control.

Oyster 2 — AOSD Hiding as Liver Disease

Up to 35% of AOSD patients develop hepatitis — often with transaminases 5–10× upper limit of normal. This triggers a hepatology workup for viral, autoimmune, or drug-induced hepatitis, and the rheumatological diagnosis is deferred. When a young patient has seronegative hepatitis, fever, and joint pain — think AOSD. The ferritin:ESR ratio and the glycosylated ferritin fraction (normal >50%; in AOSD typically <20%) are underused diagnostic tools.

Oyster 3 — Macrophage Activation Syndrome (MAS) as a Complication

MAS — also termed secondary haemophagocytic lymphohistiocytosis (HLH) — can complicate AOSD, SJIA (systemic juvenile idiopathic arthritis), and other AIS. It is potentially fatal and is heralded by a paradoxical fall in ferritin after a very high peak, pancytopenia (especially falling platelet count and WBC in a patient already febrile), rising triglycerides, and falling fibrinogen. Recognising MAS early enough to act is a life-saving skill. The 2016 MAS classification criteria (Ravelli criteria) are your go-to tool.

🦪 Oyster: In a patient with AOSD who suddenly seems "better" in the sense that fever is less spiking but they look sicker — check ferritin, triglycerides, fibrinogen, and LDH the same day. The "improvement" may be MAS consuming the cytokine storm capacity.

Oyster 4 — Sensorineural Hearing Loss in CAPS

Muckle-Wells syndrome (MWS), a moderate CAPS variant, causes progressive sensorineural hearing loss in over 70% of patients. This is not a coincidental association — it is direct cochlear inflammation from NLRP3-driven IL-1β. Audiometry should be performed at diagnosis and annually. This is reversible if treated early with IL-1 blockade; permanent if neglected.

6. ⚡ Clinical Hacks & Tips — Master Clinician Shortcuts

Hack 1 — The Ferritin Threshold

In the context of unexplained fever, ferritin >10,000 µg/L has a sensitivity of ~90% and specificity of ~96% for AOSD when combined with compatible clinical features. Use the Yamaguchi criteria (≥5 criteria, at least 2 major) as a bedside checklist:

Major: Fever ≥39°C for ≥1 week; Arthralgia/arthritis ≥2 weeks; Typical rash; WBC ≥10,000/µL with ≥80% granulocytes

Minor: Sore throat; Lymphadenopathy; Hepatosplenomegaly; Elevated LFTs; Seronegative for ANA and RF

Hack 2 — The Genetic Testing Trap

Do NOT send genetic testing as a first-line screening tool in isolation. A positive MEFV variant in a patient without classic periodic fever episodes may represent a carrier state or a low-penetrance variant — this generates diagnostic confusion, not clarity. Genetics should confirm a clinical diagnosis, not generate one. Conversely, a negative genetic test does not exclude FMF — up to 30% of clinically definite FMF patients have only one or no detectable MEFV mutation on standard panels.

⚡ Hack: Use the Eurofever/PRINTO classification criteria (validated 2019) for FMF, TRAPS, MKD/HIDS, and CAPS as your primary diagnostic framework. They integrate clinical and genetic data with appropriate weighting.

Hack 3 — The Colchicine Trial

In a patient with strong clinical suspicion for FMF and pending genetics, a therapeutic trial of colchicine (0.5–1 mg twice daily) with careful attack monitoring over 3–6 months is both diagnostically and therapeutically valuable. A dramatic reduction in attack frequency and severity strongly supports FMF. No other periodic fever syndrome responds as reliably to colchicine.

Hack 4 — When to Order SAA Over CRP

Serum amyloid A (SAA) is more sensitive than CRP for monitoring disease activity in FMF and assessing amyloid risk. In patients with FMF in clinical remission but persistent elevation of SAA between attacks, the amyloid risk remains high and treatment intensification (or addition of IL-1 blocker) should be considered, even in the absence of symptoms.

7. Diagnostic Nuances — Separating Good from Great Clinicians

7.1 The History: What to Ask and Why

The diagnostic history in AIS is highly structured. Use this framework:

Age of onset: Most monogenic AIS begin in childhood or young adulthood; AOSD peaks in 16–35 years; late-onset CAPS is being increasingly recognised
Ethnicity and ancestry: FMF in Armenians, Sephardic Jews, Turks, Arabs, Iranians; HIDS (Hyper-IgD Syndrome/MKD) in Northern Europeans; Behçet's on the "Silk Road"
Family history: Autosomal dominant (TRAPS, CAPS, NLRP12-AID); autosomal recessive (FMF, HIDS); de novo mutations common in CAPS
Attack duration: FMF 12–72 hours; TRAPS 1–3 weeks (longer attacks distinguish TRAPS from FMF); HIDS 3–7 days; PFAPA 3–6 days
Trigger factors: Cold triggers FCAS; stress and menses may trigger FMF; mevalonate kinase mutations in HIDS may flare post-vaccination
Response to prior treatments: Steroids (broad but non-specific); colchicine (specific for FMF, some PFAPA); NSAIDs (partial in many); IL-1 blockers (dramatic in CAPS, good in FMF/TRAPS/AOSD)

7.2 Examination: Don't Examine Between Attacks

This is the cardinal error. Examining a patient between attacks yields almost nothing. Whenever possible, examine the patient during a febrile episode — look for:

Rash morphology and distribution (see Pearl 3 above)
Joint swelling pattern (AOSD: predominantly wrists, knees, MCPs; FMF: large joint monoarthritis)
Serositis signs: peritoneal tenderness (FMF — can mimic acute abdomen), pleuritic chest pain (FMF, TRAPS), pericardial rub
Lymphadenopathy: prominent in AOSD, HIDS
Splenomegaly: AOSD, HIDS
Oral and genital ulcers: Behçet's (remember — Behçet's is now classified as an AIS in some frameworks)
Papilloedema: NOMID (neonatal-onset multisystem inflammatory disease) — the severe end of CAPS

7.3 Investigations — A Tiered Approach

Tier 1 — During attack (essential):

FBC with differential (neutrophilia in FMF/AOSD; transient neutropenia in HIDS)
CRP, ESR, ferritin, LDH
LFTs (hepatitis in AOSD)
Urinalysis with protein quantification
Blood cultures (to exclude infection)
Echocardiogram if chest pain (pericarditis/myocarditis)

Tier 2 — Between attacks:

Serum amyloid A (SAA) — most sensitive marker for subclinical inflammation
IgD levels (>100 IU/mL in HIDS — though 20% of HIDS may have normal IgD)
Glycosylated ferritin fraction (send to specialist lab — <20% diagnostic of AOSD)
ANA, anti-dsDNA, ANCA, RF, anti-CCP — to exclude autoimmune mimics
Complement (C3, C4) — typically normal in AIS; low in SLE mimics

Tier 3 — Specialist investigations:

Mevalonate kinase enzyme activity (HIDS)
Urine mevalonic acid during attack (HIDS)
Whole exome or targeted gene panel sequencing
Bone marrow biopsy (to exclude haematological malignancy and confirm haemophagocytosis if MAS suspected)
Abdominal fat pad biopsy or rectal biopsy (Congo red stain for amyloid)
Skin biopsy during rash (neutrophilic infiltrate in FMF erysipelas-like rash; perivascular inflammation in CAPS)

Diagnostic Principle: AIS is a clinical diagnosis supported by investigations — not the reverse. The genetic test confirms; the clinician diagnoses.

8. Management Intricacies — Drug Choices, Doses, Timing, Sequencing, and Pitfalls

8.1 Colchicine — The Foundation

FMF: Colchicine remains the cornerstone. Start at 0.5 mg twice daily, titrate to 1–1.5 mg/day based on response. The goal is complete attack suppression — partial response is not acceptable. Key pitfalls:

Under-dosing is the most common error. Many physicians stop at the first complaint of diarrhoea rather than splitting the dose or adjusting timing with food
Colchicine must be continued lifelong — stopping therapy even after years of remission leads to attack recurrence and resumes amyloid risk
Check for drug interactions: macrolide antibiotics and statins increase colchicine toxicity (P-glycoprotein and CYP3A4 inhibition); ciclosporin can cause life-threatening colchicine toxicity

8.2 IL-1 Blockade — The Game-Changer

For colchicine-resistant FMF, and as first-line or second-line therapy in CAPS, TRAPS, HIDS, and AOSD:

Drug	Mechanism	Dose	Notes
Anakinra	IL-1Ra (daily SC injection)	100 mg SC daily	Fast-acting; useful for MAS; short half-life useful if infection concern arises
Canakinumab	Anti-IL-1β monoclonal	150–300 mg SC every 8 weeks	Convenient; licensed for FMF, CAPS, TRAPS, HIDS; preferred for long-term maintenance
Rilonacept	IL-1 trap (IL-1α + IL-1β)	160 mg SC weekly	Less commonly used; licensed for CAPS

CAPS: Respond dramatically to IL-1 blockade — fever, rash, and hearing loss stabilisation often within days. Start treatment without delay once diagnosis is confirmed.

TRAPS: Etanercept has inferior efficacy compared with IL-1 blockade. Canakinumab is now preferred for frequent-attacker or steroid-dependent patients.

HIDS/MKD: IL-1 blockade (canakinumab) is effective for attack prevention. Simvastatin was once used but has largely been superseded.

8.3 AOSD — A Stepwise Strategy

Mild–moderate (systemic, no MAS): NSAIDs → prednisolone 0.5–1 mg/kg/day → methotrexate (steroid-sparing)
Moderate–severe or steroid-dependent: Tocilizumab (IL-6 blockade) or anakinra/canakinumab (IL-1 blockade) — both are effective; IL-1 blockade preferred if MAS risk is high
MAS complicating AOSD: High-dose methylprednisolone + cyclosporine; consider anakinra (can be rapidly up-titrated to 2–10 mg/kg/day); etoposide for refractory MAS

⚡ Pitfall: Hydroxychloroquine, the reflexive add-on in seronegative inflammatory diseases, has very limited efficacy in AOSD. Do not delay appropriate therapy by cycling through ineffective agents.

8.4 Biologics and Infection Risk

All IL-1 and IL-6 blockers carry infection risk, particularly:

Reactivation of tuberculosis — TB screening (Mantoux/IGRA + CXR) before initiation of all biologics; prophylactic isoniazid if latent TB
Masking of fever and sepsis — patients on IL-6 blockers (tocilizumab) may not mount CRP elevation even during severe bacterial infection; clinical suspicion must remain high
Vaccination: Live vaccines contraindicated during biologic therapy; all indicated vaccines (influenza, pneumococcal, COVID-19) should ideally be given before starting

9. When to Escalate / When to Watch

Escalate immediately if:

Ferritin rising rapidly (>10,000 µg/L with downward platelet trend) → MAS/HLH screen urgently
New proteinuria in a patient with FMF/TRAPS → amyloidosis workup; escalate to IL-1 blocker
Papilloedema or aseptic meningitis → NOMID/CAPS with CNS involvement; neurology + rheumatology emergency
Pericardial effusion with tamponade physiology → emergency drainage, consider steroid ± IL-1 blockade
Sensorineural hearing loss (new or worsening in CAPS) → urgent audiometry; treatment escalation with IL-1 blocker to prevent irreversible cochlear damage

Adopt a watch strategy if:

Mild-to-moderate attacks of FMF with good colchicine response and no inter-attack SAA elevation — continue and optimise colchicine dose
AOSD in systemic phase on adequate corticosteroids with downward ferritin trend — allow 4–6 weeks before escalating to biologics
Carrier-state MEFV heterozygote with atypical, infrequent attacks — watchful waiting, fever diary, annual urinalysis and SAA

Clinical principle: In AIS, the cost of under-treatment (organ damage, amyloidosis, permanent hearing loss) almost always exceeds the cost of early effective treatment. When in doubt — escalate.

10. State-of-the-Art Updates — What Has Changed Practice

1. Canakinumab in colchicine-resistant FMF (CLUSTER trial, 2020): A landmark phase-III trial demonstrated that canakinumab 150 mg SC every 4 weeks achieved complete response in 61% and partial response in a further 22% of colchicine-resistant FMF patients. This established canakinumab as the standard second-line agent for FMF, displacing empirical escalation to anakinra.

2. Eurofever/PRINTO Classification Criteria (2019): Validated and published classification criteria for FMF, CAPS, TRAPS, and HIDS — incorporating clinical, laboratory, and genetic variables with specific weighting. These now replace older, largely expert-consensus criteria and are the standard for clinical trials and research classification.

3. IL-18 and tadekinig alfa in AOSD/MAS: IL-18 is increasingly recognised as the dominant cytokine driver of MAS in AOSD and SJIA. Tadekinig alfa (recombinant IL-18 binding protein) has shown remarkable results in compassionate use and early trials for refractory MAS, with ongoing phase-III evaluation. This represents a potential paradigm shift for the most dangerous complication of AOSD.

4. JAK inhibitors in interferonopathies: Baricitinib (JAK1/2 inhibitor) has demonstrated efficacy in SAVI, Aicardi-Goutières syndrome, and CANDLE syndrome (proteasome-associated autoinflammatory syndrome). These were previously untreatable conditions with devastating neurological outcomes. A new treatment era has begun.

5. Treat-to-target in FMF: Emerging consensus supports targeting complete suppression of SAA (not just clinical attack prevention) as the goal in FMF management, to minimise amyloid risk. This has implications for treatment escalation decisions — asymptomatic patients with persistently elevated SAA should have therapy optimised.

11. Memorable Summary Table and Mnemonics

The FIRE Framework — Recognising AIS at the Bedside

Letter	Stands For	What to Look For
F	Fever pattern	Episodic, periodic, synchronous with symptoms
I	Inflammatory markers	Markedly elevated during attack, normalise between
R	Recurrence + Resolution	Complete resolution between episodes
E	Exclusion of infection/autoimmunity + Ethnicity/Family history	Seronegative, culture-negative, appropriate ancestry

Disease Quick-Reference: The Big Five AIS

Feature	FMF	TRAPS	HIDS/MKD	CAPS	AOSD
Gene	MEFV	TNFRSF1A	MVK	NLRP3	Unknown (polygenic)
Attack duration	12–72 h	1–3 weeks	3–7 days	Continuous	Days to weeks
Key rash	Erysipelas-like	Migratory myalgia/rash	None specific	Non-pruritic urticaria	Salmon macular
Serositis	Yes (peritoneal, pleural)	Yes (peritoneal, pleural)	Rare	Rare	Yes (pericardial)
Amyloid risk	High	High	Low	Moderate	Rare
First-line Rx	Colchicine	NSAIDs/steroids → IL-1	Supportive → IL-1	IL-1 blockade	NSAIDs/steroids
IL-1 licensed drug	Canakinumab	Canakinumab	Canakinumab	Canakinumab/Rilonacept	Anakinra/Canakinumab

Mnemonic for AOSD Diagnosis — SOFT RASH

S — Seronegative (RF and ANA negative)
O — Organomegaly (hepatosplenomegaly)
F — Ferritin sky-high (>10,000 µg/L)
T — Throat sore (pharyngitis at onset)
R — Rash — salmon, evanescent, synchronous with fever
A — Arthritis/arthralgia
S — Spike fever (quotidian, ≥39°C)
H — High WBC (≥10,000/µL, neutrophil predominant)

Red Flags Demanding Urgent Action

🚨 Do not wait. Act the same day.

Ferritin >10,000 µg/L + falling platelets → Screen for MAS

New proteinuria in FMF/TRAPS → Amyloid biopsy

Sensorineural hearing loss in CAPS → IL-1 blocker same week

Papilloedema/CNS signs → NOMID; neurology emergency

Fever + severe abdominal pain in FMF → Exclude perforation before labelling as FMF attack

12. References

Infevers: An online database for autoinflammatory mutations. Sarrauste de Menthière C, et al. Nucleic Acids Research. 2003;31(1):282–285.
Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75(4):644–651.
de Jesus AA, Goldbach-Mansky R. Monogenic autoinflammatory diseases: concept and clinical manifestations. Clin Immunol. 2013;147(3):155–174.
Gattorno M, Hofer M, Federici S, et al. Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis. 2019;78(8):1025–1032.
De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the treatment of autoinflammatory recurrent fevers in Europe. N Engl J Med. 2018;378(20):1908–1919.
Barsalou J, Cofer L, Benseler S, et al. Autoinflammatory diseases in childhood. Pediatr Clin North Am. 2018;65(4):701–723.
Ravelli A, Minoia F, Davi S, et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2016;75(3):481–489.
Fautrel B. Adult-onset Still disease. Best Pract Res Clin Rheumatol. 2008;22(5):773–792.
Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell. 2010;140(6):784–790.
Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2011;70(5):747–754.
Manthiram K, Zhou Q, Aksentijevich I, Kastner DL. The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat Immunol. 2017;18(8):832–842.
Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396–2406.
Laskari K, Boura P, Dalekos GN, et al. Longterm outcome of systemic lupus erythematosus-related inflammatory myopathy. Arthritis Care Res (Hoboken). 2018;70(10):1483–1490.
Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still's disease. Nat Rev Rheumatol. 2018;14(10):603–618.
Kim HA, Sung JM, Suh CH. Therapeutic responses and prognosis in adult-onset Still's disease. Rheumatol Int. 2012;32(5):1291–1298.

Author's Note

The field of autoinflammatory syndromes is moving at a pace that rewards the curious clinician. From the bench discovery of the inflammasome to the bedside deployment of IL-1 inhibitors that transform lives within days — this is modern internal medicine at its most intellectually satisfying. The patient who has seen twelve physicians deserves a thirteenth who thinks differently. Be that clinician.

Word count: ~3,200 | Formatted for postgraduate medical education | Review category: Rheumatology/Immunology within Internal Medicine

Search This Blog

Internal medicine